Last update March 9, 2021
Very Low Risk
Non-steroidal anti-inflammatory drug (NSAID), that functions as a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme.
Prescribed for the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
Daily oral administration in one or two doses.
Pharmacokinetic data (large volume of distribution and high percentage of protein binding) can explain the observed negligible or null passage into breastmilk, which is not clinically significant (Ruhlen 2007, Gardiner 2006, Hale 2004, Knoppert 2003).
No problems have been reported in infants of mothers that took these drugs (Hale 2004).
The plasma levels of these infants were undetectable or very low (Hale 2004).
Pediatric use authorized in children 2 years of age and older.
Use of this medication is regarded as safe during breastfeeding by various medical societies and expert consensus (Reece 2017, Noviani 2016, Götestam 2016, Briggs 2015, Matsota 2013, Sachs 2013, Østensen 2007).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM